Matrix-Bio´s sophisticated blood-based metabolite profiling diagnostic tests powered by the VeraMarker™ technology platform detect the presence and reoccurrence of cancer and monitor treatment with greater accuracy, speed, and less patient discomfort than current diagnostic testing. Not only are we redefining cancer detection, we're redefining hope.
Matrix-Bio Signs Global Licensing and Marketing Agreement With Quest Diagnostics for Metabolomics Biomarkers Used to Detect Breast Cancer Recurrence. MORE>
There are currently 2.5 million breast cancer survivors who may benefit from recurrence monitoring. This new recurrence-monitoring test measures key metabolic changes to quickly and accurately detect the return of cancer.
Our VeraMarker™ technology platform opens the door to new, more accurate diagnostic tests and investor opportunities.
Boston’s New England Venture Summit to Showcase Cancer Metabolomics Diagnostics Leader Matrix-Bio
Matrix-Bio, Inc. is a featured startup company at the 8th annual New England Venture Summit on December 11 at the Hilton Boston Dedham.
What is metabolite profiling? How does it benefit breast cancer patients and their physicians?